Your AI-Trained Oncology Knowledge Connection!

Around the Practice: Optimizing Patient Care for Advanced Non–Clear Cell RCC : Episode 8

KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

September 27, 2024

By Moshe Ornstein, MD, MA
Karine Tawagi, MD

Opinion

Video

Medical experts examine how overall survival data from KEYNOTE-564 has influenced the use of pembrolizumab as adjuvant therapy.

EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell

EP: 2.Challenges in Treating RCC From Community and Academic Settings

EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 5.nccRCC: Alternative Therapies

EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC

EP: 7.AE Management of IO/TKI and Future of nccRCC

EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

EP: 9.NCCN Guideline Updates in Clear-Cell RCC

EP: 10.Best Treatment Selection in Clear-Cell RCC

Video content above is prompted by the following:

How has overall survival data from KEYNOTE-564 impacted the use of pembrolizumab as adjuvant therapy?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

1 expert is featured in this series.

2 experts are featured in this series.

2 experts are featured in this series.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.